文献速递神经肿瘤

302例非典型脑膜瘤的治疗方案、长期随访及死亡预测因素

Treatment Protocol, Long-Term Follow-Up, and Predictors of Mortality in 302 Cases of Atypical Meningioma.
PubMed 文献 · World Neurosurg · 2018-11-14

该研究回顾了2008年1月至2015年12月在本机构接受手术的302例非典型脑膜瘤患者,分析生存预测因素及术后放疗的作用。中位随访41.6个月,全切除201例(66.6%),术后放疗75例(24.8%),复发131例(43.4%),死亡56例(18.5%)。多因素分析显示术前KPS≥80、原发肿瘤、肿瘤侵袭性及全切除与无复发生存增加相关;术前KPS≥80、原发肿瘤、幕上位置、无瘤周水肿、放疗及全切除与总生存增加相关。作者认为全切除是首选,建议继发性肿瘤患者术后放疗。

要点

  • 全切除201例(66.6%),术后放疗75例(24.8%),中位随访41.6个月。
  • 中位无复发生存55.2个月,1年、3年、5年无复发生存率分别为87.6%、63.3%、47.7%。
  • 中位总生存99.8个月,1年、3年、5年总生存率分别为97.0%、90.6%、78.8%。

核心结论

  • 作者认为全切除是非典型脑膜瘤患者的首选治疗。
  • 作者建议继发性肿瘤患者术后接受放疗。

研究设计与样本

  • 回顾性分析2008年1月至2015年12月在本机构接受手术的302例非典型脑膜瘤患者,其中女性166例、男性136例。

主要发现

  • 全切除201例(66.6%),术后放疗75例(24.8%)。
  • 中位随访41.6个月,复发131例(43.4%),转移1例(0.33%),死亡56例(18.5%)。
  • 中位无复发生存55.2个月,1年、3年、5年无复发生存率分别为87.6%、63.3%、47.7%。
  • 中位总生存99.8个月,1年、3年、5年总生存率分别为97.0%、90.6%、78.8%。
  • 多因素分析中,术前KPS≥80、原发肿瘤、肿瘤侵袭性及全切除与无复发生存增加相关;术前KPS≥80、原发肿瘤、幕上位置、无瘤周水肿、放疗及全切除与总生存增加相关。

关键数值与推荐

  • 术前KPS评分≥80、原发肿瘤、肿瘤侵袭性、全切除与无复发生存增加相关。
  • 术前KPS评分≥80、原发肿瘤、幕上位置、无瘤周水肿、放疗、全切除与总生存增加相关。

临床怎么用

  • 作者认为全切除是非典型脑膜瘤患者的首选治疗。
  • 作者建议继发性肿瘤患者术后接受放疗。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Because of the paucity of relevant data, treatment and outcomes in intracranial atypical meningioma (AM) remain unclear. The aim of this study was to find useful factors predicting survival and to evaluate the role of postoperative radiation after surgery. METHODS: Data were obtained from 302 patients with AM who underwent surgery between January 2008 and December 2015. RESULTS: A series of 302 patients, including 166 female and 136 male, underwent surgery at our institution. Gross total resection (GTR) was achieved in 201 (66.6%) patients. Seventy-five patients (24.8%) underwent postoperative radiation after surgery. For the entire cohort, there were 131 (43.4%) recurrences, 1 (0.33%) metastasis, and 56 (18.5%) mortalities during a median follow-up duration of 41.6 months. The median recurrence-free survival (RFS) was 55.2 months after the date of the first AM surgery, with 1-year, 3-year, and 5-year RFS rates of 87.6%, 63.3% and 47.7%, respectively. The median overall survival (OS) for patients was 99.8 months, and the actuarial OS rates from the time of the first AM surgery at 1, 3, and 5 years were 97.0%, 90.6%, and 78.8%, respectively. In multivariate analysis, preoperative Karnofsky Performance Scale score (≥80), primary tumor, tumor invasiveness, and GTR were associated with increased RFS, whereas preoperative Karnofsky Performance Scale score (≥80), primary tumor, supratentorial location, lack of peritumoral edema, radiotherapy, and GTR were associated with increased OS. CONCLUSIONS: GTR is the first choice for patients with AM. We recommend that patients with secondary tumors receive radiotherapy after surgery.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Li H, Zhang YS, Zhang GB, et al. Treatment Protocol, Long-Term Follow-Up, and Predictors of Mortality in 302 Cases of Atypical Meningioma. World Neurosurg. 2018. PMID: 30447439. doi:10.1016/j.wneu.2018.11.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。